VRDN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Viridian Therapeutics Inc (VRDN) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has promising catalysts in 2026, such as FDA reviews and Phase 3 trial results, the recent pre-market price drop, lack of proprietary trading signals, and negative sentiment from Commodore Capital's exit suggest caution. Additionally, the company missed Q4 revenue expectations, and its financial performance shows declining net income and EPS despite revenue growth. For now, holding the stock and monitoring upcoming catalysts is recommended.
The technical indicators show mixed signals. The MACD is positive and expanding, suggesting bullish momentum, but the RSI is neutral at 58.045. Moving averages are converging, indicating a lack of a clear trend. Key support is at 28.42, with resistance levels at 30.02 and 31.009. The pre-market price of $28.99 is near the pivot point, suggesting limited immediate upside.
and Phase 3 trial results in Q1 and Q2
Analysts maintain high price targets ($44-$
and positive ratings, citing the company's competitive advantages over existing treatments.
Commodore Capital's complete exit from its 3.2 million shares signals potential concerns about the company's short-term outlook. Q4 financial results missed revenue expectations significantly, and the pre-market price drop (-1.70%) reflects negative sentiment.
In Q4 2025, revenue grew 85.7% YoY to $0.13M but missed expectations by $15.62M. Net income dropped 54.88% YoY to -$34.6M, and EPS declined 63.48% YoY to -$1.08. The gross margin remained strong at 100%, but the company is still unprofitable.
Analysts are bullish, with multiple firms raising price targets to $44-$50 and maintaining Buy or Outperform ratings. They highlight the company's innovative treatments and potential market share capture in the thyroid eye disease market.
